Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Income from Continuing Operations (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Income from Continuing Operations for 15 consecutive years, with 623000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 89.09% year-over-year to 623000.0, compared with a TTM value of 6443000.0 through Sep 2025, down 588.35%, and an annual FY2024 reading of 436000.0, up 97.28% over the prior year.
  • Income from Continuing Operations was 623000.0 for Q3 2025 at Fennec Pharmaceuticals, up from 3155000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 12906000.0 in Q1 2024 and bottomed at 6895000.0 in Q4 2022.
  • Average Income from Continuing Operations over 5 years is 2877705.88, with a median of 3917000.0 recorded in 2021.
  • Peak annual rise in Income from Continuing Operations hit 316.58% in 2024, while the deepest fall reached 222.47% in 2024.
  • Year by year, Income from Continuing Operations stood at 4109000.0 in 2021, then crashed by 67.8% to 6895000.0 in 2022, then soared by 62.03% to 2618000.0 in 2023, then skyrocketed by 42.67% to 1501000.0 in 2024, then surged by 58.49% to 623000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for FENC at 623000.0 in Q3 2025, 3155000.0 in Q2 2025, and 1164000.0 in Q1 2025.